恶性淋巴瘤是欧美国家常见的造血系统恶性肿瘤,其发病率逐年上升.大多数滤泡型非霍奇金淋巴瘤多为慢性、难治性恶性肿瘤,易复发,治疗困难.现有的治疗方案包括化疗、放疗、单克隆抗体介导的免疫治疗、放射免疫治疗及造血干细胞移植治疗.放射性核素131I和90 Y标记的单克隆抗体的放射免疫治疗的疗效有待于进一步研究.%Non-Hodgkin's lymphoma (NHL) is the most common hematological malignancy in the United States with a rapidly increasing incidence. Most follicular NHL is indolent but incurable, Most patients with follicular NHL who transform to an aggressive NHL are very difficult to treat successfully. Treatment options have included chemotherapy, radiation, immunotherapy with monoclonal antibodies, alone or in combination, and hematopoietic stem cell transplantation. The efficacy of monoclonal antibodies is augmented when they are combined with a radioisotope like iodine-131 or yttrium-90. There have been a number of studies done in recent years studying the efficacy of this form of therapy, i.e., radioimmunotherapy (RIT) in patients with NHL. This review attempts to integrate the information from the various clinical trials done using RIT in patients with relapsed/refractory or newly diagnosed NHL.
展开▼
